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Abstract
Aims
Short QT syndrome (SQTS) is an inherited disorder associated with abnormally abbreviated
QT intervals and an increased incidence of atrial and ventricular arrhythmias. SQT1 variant
(linked to the rapid delayed rectifier potassium channel current, IKr) of SQTS, results from an
inactivation-attenuated, gain-of-function mutation (N588K) in the KCNH2-encoded potas-
sium channels. Pro-arrhythmogenic effects of SQT1 have been well characterized, but less
is known about the possible pharmacological antiarrhythmic treatment of SQT1. Therefore,
this study aimed to assess the potential effects of E-4031, disopyramide and quinidine on
SQT1 using a mathematical model of human ventricular electrophysiology.
Methods
The ten Tusscher et al. biophysically detailed model of the human ventricular action poten-
tial (AP) was modified to incorporate IKr Markov chain (MC) formulations based on experi-
mental data of the kinetics of the N588K mutation of the KCNH2-encoded subunit of the IKr
channels. The modified ventricular cell model was then integrated into one-dimensional
(1D) strand, 2D regular and realistic tissues with transmural heterogeneities. The channel-
blocking effect of the drugs on ion currents in healthy and SQT1 cells was modeled using
half-maximal inhibitory concentration (IC50) and Hill coefficient (nH) values from literatures.
Effects of drugs on cell AP duration (APD), effective refractory period (ERP) and pseudo-
ECG traces were calculated. Effects of drugs on the ventricular temporal and spatial vulner-
ability to re-entrant excitation waves were measured. Re-entry was simulated in both 2D
regular and realistic ventricular tissue.
Results
At the single cell level, the drugs E-4031 and disopyramide had hardly noticeable effects on
the ventricular cell APD at 90% repolarization (APD90), whereas quinidine caused a signifi-
cant prolongation of APD90. Quinidine prolonged and decreased the maximal transmural AP
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heterogeneity (δV); this led to the decreased transmural heterogeneity of APD across the
1D strand. Quinidine caused QT prolongation and a decrease in the T-wave amplitude, and
increased ERP and decreased temporal susceptibility of the tissue to the initiation of re-
entry and increased the minimum substrate size necessary to prevent re-entry in the 2D reg-
ular model, and further terminated re-entrant waves in the 2D realistic model. Quinidine
exhibited significantly better therapeutic effects on SQT1 than E-4031 and disopyramide.
Conclusions
The simulated pharmacological actions of quinidine exhibited antiarrhythmic effects on
SQT1. This study substantiates a causal link between quinidine and QT interval prolonga-
tion in SQT1 and suggests that quinidine may be a potential pharmacological agent for treat-
ing SQT1 patients.
Introduction
Short QT syndrome (SQTS) is a cardiac disorder associated with abnormally abbreviated QT
intervals and an increased incidence of atrial and ventricular arrhythmias or sudden cardiac
death (SCD) [1–4]. Short QT interval in SQTS is commonly less than 360 ms with a range of
220 to 360 ms; another important feature in SQTS is the tall, symmetrical or asymmetrical
peaked T wave morphology. The term ‘short QT interval’ was first described by Gussak et al.
[1] in 2000, and it was recognized as the distinct clinical entity. The familial nature and charac-
teristics of this sudden death syndrome were simply demonstrated by Gaita et al. [2] in 2003.
These reports led to the recognition of SQTS as a new, distinct disease and have been quickly
followed by additional human case reports over the past decade. The molecular basis for SQTS
associated with various mutations in 6 different genes: KCNH2 [5], KCNQ1 [6], KCNJ2 [7],
CACNA1C [8], CACNB2b [8] and CACNA2D1 [9], have been reported. The corresponding
short QT syndrome has been termed from SQT1 to SQT6 depending on the chronological
order of discovery. Among these dominant mutations, either a gain-in-function of the potas-
sium channel (linked to KCNH2, KCNQ1 and KCNJ2 gene) or a loss-in-function of the calcium
channel (linked to CACNA1C, CACNB2b and CACNA2D1 gene) across the membrane of car-
diac muscle cells has been observed.
KCNH2-linked short QT syndrome (SQT1) was first identified in a 51-year-old male pre-
senting a corrected QT interval (QTc) of 288 ms. Based on genetic analysis of KCNH2, a single
amino-acid residue substitution (asparagine-to-lysine, N588K) in the turret (also called S5-
pore linker) region of the human ether-à-go-go-related gene (hERG) potassium channels was
discovered. Results from in vitro standard whole-cell patch clamp recordings have revealed
that this mutation leads to an increased activity of rapid delayed rectifier potassium current
(IKr) in the hERG potassium channels. The N588K mutation leads to loss of normal rectifica-
tion of IKr over the physiological range of membrane potentials, resulting in a substantial gain
of function during phase 2 and 3 of the cardiac action potential (AP), and thereby accelerated
ventricular repolarization [5,10,11]. In the previous studies, Itoh et al. [12] and Adeniran et al.
[13] investigated the mechanisms how KCNH2 gene-mediated channel defects cause life-
threatening arrhythmias in SQT1, and have in detailed shown that SQT1 abbreviated the AP
duration (APD) and effective refractory period (ERP) and reduced the maximal slopes of APD
restitution (APD-R) and ERP restitution (ERP-R) curves, which was consistent with the poor
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rate-dependent of QT intervals and consequently shortened the QT interval and raised the T-
wave amplitude in SQT1 patients.
Due to the malignant ventricular arrhythmia in SQTS, the implantable cardioverter defi-
brillator (ICD) is primarily recommended for patients with a diagnosis of SQTS. Despite the
success of this technique, a problem with ICD in SQTS is an increased risk of an inappropriate
shock from the ICD. Moreover, the QT interval does not fall within the normal range over
time by using the ICD. SQTS patients may benefit from subcutaneous ICD therapy, but addi-
tional clinical cases are needed to affirm the efficacy and safety of such device [14]. Although
the ICD remains the mainstay of treatment for SQTS patients, pharmacological therapy may
be useful as an adjunct to the ICD therapy or may restore the normal QT interval and suppress
atrial and ventricular fibrillation. However, to date, available data regarding pharmacological
treatment for SQTS patients are very limited. An in vivo study by Gaita et al. [15] tested four
antiarrhythmic drugs including hydroquinidine, flecainide, ibutilide and sotalo in SQT1
patients, to determine whether they could prolong the QT interval into the normal range.
They reported quinidine prolonged the QT interval and ERP and effectively prevented ventric-
ular arrhythmias in SQT1 patients [15]. Quinidine also restored the QT interval toward the
normal range [16]. In a one-year follow-up, the SQT1 patients who treat with hydroquinidine
remained asymptomatic, and no further episode of arrhythmias was detected. An in vitro
study by McPate et al. [17] evaluated the impact of selected class I and class III five antiarrhyth-
mic drugs including E-4031, disopyramide, amiodarone, quinidine and propafenone on SQT1
N588K mutant channels.
In summary, pharmacological treatment for SQTS patients has not yet been established.
Quinidine seems to be a first-line therapeutic option in patients with SQTS. However, little
is known about the mechanisms of actions of quinidine on SQT1. Moreover, drugs exert
effects spanning multiscale levels from ion channel to tissue, organ and whole body, making
investigation using experimental technique tough and rather expensive [18]. In silico mod-
els of the heart provide a powerful means of investigating some questions that do not lend
themselves readily to in vitro or in vivo studies. Elucidating pharmacological effects of drugs
on SQTS falls into this category as it is not easy to conceive of biological experiments that
would accurately assess the effects of drugs on the known SQTS. Furthermore, several
recent reviews [19–23] have highlighted the power of in silico models to investigate arrhyth-
mias and predict pharmacological effects of drugs. Recent studies [18,24–26] have explicitly
shown that in silico models have proven to be useful in predicting the effects of drugs on
arrhythmias. Therefore, this study was undertaken to assess the effects of quinidine on
SQT1 by using computational human ventricular cell and tissue models, and consequent
effects on QT interval prolongation and prevention and termination of re-entrant ventricu-
lar arrhythmias in this variant of SQTS.
Materials and methods
Model development
The ten Tusscher et al. [27] biophysically detailed computer model for human endocardial
(ENDO), mid-myocardial (MIDDLE) and epicardial (EPI) ventricular APs was used in this
study. IKr dynamic equations in the original model were replaced with a previously-described
Markov chain (MC) formulation [13] of hERG wild-type (WT) and N588K IKr channel. These
properties include that (i) a shift in the voltage-dependence of mutant IKr channel, and (ii) an
increased IKr during the repolarization phase in the AP [5,11,17,28]. A schematic for the IKr
MC model is shown in Fig 1. The IKr MC model made up of an open state (OKr), three closed
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states (C1, C2 and C3), and an inactivated state (I), which is described as:
IKr ¼ GKr  OKr  ðV   EKrÞ ð1Þ











C1 ¼ b  C2   a  C1 ð4Þ
C2 ¼ a  C1   b  C2 þ b1  C3   a1  C2 ð5Þ
C3 ¼ a1  C2   b1  C3   2  a2  C3 þ m  I þ b2  OKr ð6Þ
I ¼ a2  C3   m  I þ ai  OKr   bi  I ð7Þ
OKr ¼ 1   ðC1 þ C2 þ C3 þ IÞ ð8Þ
where GKr is the maximal conductance, OKr is the open probability, [K+]o and [K+]i are extra-
cellular and intracellular K+ concentration, respectively. V is the transmembrane potential and
EKr is the K+ equilibrium (or reversal) potential. Modified IKr formulations for WT and N588K
conditions are shown in the Supporting Information.
A simple pore block theory [29] was used to model drug/ion channel binding interactions.
The maximum conductance of cardiac specific ion channels was reduced according to the Hill
equation. The respective reduction of ion currents in the presence of E-4031, disopyramide or
quinidine was determined by using half maximal inhibitory concentration (IC50) and Hill
coefficient (nH) values taken from literatures. The blocking potency of these drugs on ionic
currents is shown in Table 1, Table 2 and Table 3, respectively. E-4031 is a pure IKr blocker
[30] and it does not affect the Na+ and Ca2+ inward currents [31], whereas disopyramide and
quinidine are multiple current blockers [15,32]. The therapeutic concentration of E-4031 is
3~4 nM [33], disopyramide is 8.3~13.0 μM (corresponding to be 2.8~4.4 mg/L) [34], and
Fig 1. A schematic for the IKr MC model used in this study. OKr is the open state. C1-C3 are the closed
states. I is the inactivated state.
https://doi.org/10.1371/journal.pone.0179515.g001
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quinidine is 3.8~10.2 μM [35]. Several doses (3.0, 3.5 and 4.0 nM for E-4031, 9, 10 and 13 μM
for disopyramide, and 4, 7 and 10 μM for quinidine) were selected and simulated to compare
the effects on SQT1 related N588K mutation in KCNH2.
Single cell model and AP simulations
The validated IKr MC model was then incorporated into the ten Tusscher et al. [27] cell model.








where t is time, Cm is the cell membrane capacitance per unit surface area, Istim is the external
stimulus current and Iion is the sum of all transmembrane ionic currents. Particularly, the compo-
nent of the late sodium current (INaL) from the ORd dynamic model [36] was incorporated. The
model code used in this study was downloaded from http://www-binf.bio.uu.nl/khwjtuss/. The
cell model was paced with an amplitude of -52 pA/pF for 1 ms and a basic cycle length (BCL) of
800 ms, which roughly corresponds to 75 bpm of the normal human heart. After the pacing, the
resulting ventricular cell APD at 90% repolarization (APD90) of the WT and N588K ENDO,
MIDDLE and EPI cells were measured. APs were elicited with an S1-S2 protocol consisting of 20
S1 stimuli and an S2 stimulus. The S1 was applied at a frequency of 1.25 Hz and -52 pA/pF
strength for 1 ms. The S2 was applied at varying diastolic intervals (DI) after the AP-evoked by
the last S1. The APD-R curve was generated by decreasing the DIs and plotting the APD90 evoked
by the S2 against the DIs. The ERP was measured as the smallest DI for which the overshoot of
the AP- evoked by the S2 reached 80% of the AP-evoked by the 20th S1 at each pacing cycle length
(PCL) [37]. The ERP-R curve was generated by plotting the measured EPR against PCLs. Eq 9
was integrated by using the forward Euler method with a time step of 0.02 ms.
Tissue simulations





¼   ðIion þ IstimÞ þ r  ðDrVÞ; ð10Þ
Table 1. Cardiac ion currents and conductivities (% of original value) in the presence of 3.0, 3.5 and 4.0 nM E-4031.
Current IC50 nH Conductivity Source
WT IKr 15.96±0.04 nM 0.74±0.05 86.0/83.2/80.0% [17,38]
N588K IKr 183±0.04 nM 1.07±0.04 99.0/98.8/98.0%
https://doi.org/10.1371/journal.pone.0179515.t001
Table 2. Cardiac ion currents and conductivities (% of original value) in the presence of 9, 10 and 13 μM disopyramide.
Current IC50 nH Conductivity Source
WT IKr 10.66±0.04 nM 1.07±0.05 60.0/51.7/39.1% [17,38]
WT INa 168.4 μM 1.09 96.7/95.6/95.0% [39]
WT Ito 259 μM 1.07 97.6/97.0/94.3% [32]
WT ICaL 1036.7 μM 1.0 99.3/99.0/98.7% [39]
N588K IKr 15.77±0.04 μM 0.63±0.04 63.9/57.1/49.1% [17,38]
N588K INa 168.4 μM 1.09 96.7/95.6/95.0% [39]
N588K Ito 259 μM 1.07 97.6/97.0/94.3% [32]
N588K ICaL 1036.7 μM 1.0 99.3/99.0/98.7% [39]
https://doi.org/10.1371/journal.pone.0179515.t002
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wherer is the spatial gradient operator, D is the diffusion coefficient between ventricular
cells.
For one-dimensional (1D) computations, the simulated 1D strand (Fig 2) was 15 mm and
employed a spatial resolution of 0.15 mm, close to the ventricular cell length of 80–150 μm,
which generated 25 nodes for ENDO (25%), 35 nodes for MIDDLE (35%) and 40 nodes for
EPI (40%) cells. Drouin et al. [44] reported a 10 to 12 mm thickness of transmural slices. Yan
et al. [45] reported an average thickness of the wedge preparations of 12.9 ± 1.5 mm. The total
length of the 1D strand shows close agreement with these experimental data. The lengths of
each sub-region were 3.75 mm, 5.25 mm and 6 mm. The total strand length and proportion
for each sub-region are identical to those used in other studies [13,37,46,47] and reliably repro-
duced a positive T wave in the simulated pseudo-ECG in the control condition. The stimula-
tion protocol (amplitude: -52 pA/pF, duration: 1 ms) was shown in Fig 2A. We constructed
ENDO-ENDO (Fig 2B), ENDO-MIDDLE-EPI (Fig 2C) and EPI-EPI (Fig 2D) connection in
the 1D cable models. Dwas set at 0.0008 cm2/ms, which promoted an electrical excitation con-
duction velocity (CV) of 52 cm/s through the 1D strand, which is close to the experimental CV
of ~50 cm/s [48,49]. D was homogenous except for a 5-fold decrease at the MIDDLE-EPI junc-
tion, as previously suggested by Gima and Rudy [50].
A pseudo-ECG was calculated as an integral of the transmural gradient of the cell APs at all










where α is the radius of the 1D simulated strand, dx is the spatial resolution, r is the Euclidean
distance from a strand point x to the electrode point x0. In this study, we placed the virtual elec-
trode at a position 2.0 cm away from the EPI end of the strand. The QT interval was calculated
as the time interval determined by definition of the Q-wave onset (Qonset = 0.0 mV, t = 0 ms)
and the point corresponding to the T-wave end (Tend). The time, at which the ECG data fell
below a threshold (Vthresh = 0.01 mV) was defined as Tend.
Table 3. Cardiac ion currents and conductivities (% of original value) in the presence of 4, 7 and 10 μM quinidine.
Current IC50 nH Conductivity Source
WT IKr 0.62±0.03 μM 0.93±0.06 17.0/10.0/7.0% [17,38]
WT IKs Not given Not given 75.0/60.0/45.2% [40]
WT Ito 3.9 μM 1.0 46.5/38.9/25.3% [41]
WT INa 0.17 nM 1.0 79.6/77.0/59.3% [42]
WT ICaL 14.9±1.5 μM 1.1±0.1 83.2/72.9/61.2% [43]
WT INaCa Not given Not given 95.0/90.0/86.5% [43]
WT INaL 12.0±0.7 μM 1.0 28.3/37.7/52.3% [35]
N588K IKr 2.16±0.02 μM 0.92±0.04 44.0/29.8/19.1% [17,38]
N588K IKs Not given Not given 75.0/60.0/45.2% [40]
N588K Ito 3.9 μM 1.0 465.6/38.9/25.3% [41]
N588K INa 0.17 nM 1.0 79.6/77.0/59.3% [42]
N588K ICaL 14.9±1.5 μM 1.1±0.1 83.2/72.9/61.2% [43]
N588K INaCa Not given Not given 95.0/90.0/86.5% [43]
N588K INaL 12.0±0.7 μM 1.0 28.3/37.7/52.3% [35]
Effects of a combined action of blocking of multiple ion currents in the presence of quinidine at 4, 7 and 10 μM doses together with theoretical (75.0 and
60.0%) and experimental (45.2%) blocking of IKs and with theoretical (95.0 and 90.0%) and experimental (86.5%) blocking of INaCa.
https://doi.org/10.1371/journal.pone.0179515.t003
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A regular 2D simulated transmural tissue was modeled by expanding the 1D strand (length
of 15 mm) with a width of 150 mm (Fig 2E). The spatial resolution in both length- and width-
directions was the same as used in the 1D strand model. In the regular model, re-entrant exci-
tation wave was initiated by an S1-S2 protocol. An S1 stimulus (amplitude: -52 pA/pF, dura-
tion: 1 ms) was applied to the ENDO end to evoke a planar excitation wave propagating
through MIDDLE towards the EPI end. During the vulnerable window (vulnerable window,
during which stimulation produces a solitary wave that propagates in either the anterograde or
retrograde direction, is the time window which results in unidirectional block that allows re-
entry), an S2 stimulus with the same amplitude and duration as the S1 was applied to the MID-
DLE-EPI junction area to evoke unidirectional wave propagation. This action led to the gener-
ation of a re-entry that then progressively rotated through the tissue. However, the S2 had
variable spatial sizes. Sufficient S2 size is required to provide an adequate re-entrant pathway,
which is dependent on the wavelength (wavelength = ERP×CV) of excitation waves. In order
to evaluate the critical size of the re-entrant pathway, we estimated the minimum length of S2.
This length is an index which indicates the susceptibility of the ventricular tissue to re-entry,
i.e., the larger the minimum length, the more difficult the initiation of re-entrant excitation
waves. The dominant frequency (DF) of the AP profile from a special site was computed from
Fig 2. Schematic representation of the 1D strand and 2D regular and realistic models. (A) S1-S2 stimulus protocol. (B) ENDO-to-ENDO connection of
a 1D strand model. (C) 1D transmural ventricular strand model. The virtual electrode was placed at a position 2.0 cm away from the EPI end of the strand. (D)
EPI-to-EPI connection of a 1D strand model. (E) Schematic representation of the 2D regular model. (F) 2D realistic model.
https://doi.org/10.1371/journal.pone.0179515.g002
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a time interval between two neighbor AP amplitudes, whose reciprocal provides a measure of
the DF. For such an initiated wave, effects of E-4031, disopyramide and quinidine on dynam-
ical behaviors were evaluated in the SQT1 condition. In the 2D realistic model (including
11343 ENDO cells, 6565 MIDDLE cells and 16229 EPI cells), the S1-S2 protocol was applied in
the ENDO of the left ventricle (Fig 2F). The S2-evoked excitation wave propagates unidirec-
tionally, leading to the formation of re-entrant excitation wave within the transmural wall.
Results
Effects of E-4031, disopyramide and quinidine on SQT1 in the cell model
Fig 3 shows the simulation of APs and IKr profile and channel states in the ENDO (Fig 3A),
MIDDLE (Fig 3B) and EPI (Fig 3C) cell model with the MC IKr in the WT and N588K condi-
tions. Fig 4 exhibits the time course of the EPI cell AP waveforms, APD90 (Fig 4A) and IKr cur-
rent profile/peak density (Fig 4B) in the E-4031-, disopyramide- and quinidine-in-action
conditions. AP waveforms show the cardiac myocyte transmembrane potential V (mV) versus
time t (ms). The results indicate the following: (i) the WT IKr increased during the time course
Fig 3. Simulation of APs and IKr time course and channel states. (A) ENDO simulation of steady state APs (i), corresponding IKr current profiles (ii),
inactivation, open and closed states of the IKr channels in WT (iii) and N588K (iv) conditions using the IKr Markov chain model. Solid black lines represent WT
and dashed black lines represent N588K condition. Solid gray lines represent the open state, dashed gray lines represent inactivated state, and thick dashed
gray lines represent the closed state. (B) MIDDLE simulation of steady state APs (i), corresponding IKr current profiles (ii), inactivation, open and closed
states of the IKr channels in WT (iii) and N588K (iv) conditions. (C) EPI simulation of steady state APs (i), corresponding IKr current profiles (ii), inactivation,
open and closed states of the IKr channels in WT (iii) and N588K (iv) conditions.
https://doi.org/10.1371/journal.pone.0179515.g003
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of the upstroke and plateau phases of the AP, reaching the peak amplitude before a rapid
decrease during the final rapid repolarization phase; (ii) The N588K mutant IKr increased
more rapidly following the upstroke phase and reached a higher amplitude, leading to APD-
shortening effect; (iii) The simulated E-4031 and disopyramide had hardly noticeable effects
on APD, whereas quinidine caused a prolongation of APD both in WT and N588K conditions;
quinidine at a dose of 10 μM produced a significant prolongation of the APD in the N588K
condition, bring it much closer to that in the WT drug-free condition; (iv) Simulated drugs
markedly affected the AP peak amplitude but did not affect the resting potential (RP). The
effects are due to the reduction of channel conductance, which depends on the actions of
drugs that decelerate the repolarization process.
Effects of E-4031, disopyramide and quinidine on SQT1 in the 1D strand
model
We then simulated the effects of E-4031, disopyramide and quinidine on the electrical activity
of the ventricle and the pseudo-ECG traces using the 1D strand model (including ENDO-to-
ENDO connection, transmural and EPI-to-EPI connection forms described in the Methods
section) at a stimulation frequency of 1.25 Hz. The results are presented in Fig 5. Delivery of a
series of super-threshold stimuli (-52 pA/pF) to one end initiated electrical propagation
Fig 4. Effects of E-4031, disopyramide and quinidine on human ventricular EPI cells. (A) AP waveforms (i) and corresponding APD90 histogram in WT
(ii) and N588K (iii) conditions. (B) IKr current profile (i) and peak density in WT (ii) and N588K (iii) conditions. Dashed black lines represent WT condition and
solid black lines represent N588K condition. Dashed gray lines represent WT+10μM quinidine condition and solid gray lines represent N588K+10μM
quinidine condition.
https://doi.org/10.1371/journal.pone.0179515.g004
Effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1
PLOS ONE | https://doi.org/10.1371/journal.pone.0179515 June 20, 2017 9 / 22
towards the other end of the 1D strand model. From this electrical excitation wave, pseudo-
ECG traces were simulated. However, in our initial simulations, the 1D strand model failed to
reproduce an unusual increase in the T-wave amplitude recorded from SQT1 patients. To
solve this discrepancy problem, an IKr ratio of 1.6:1:1 in the EPI, MIDDLE and ENDO cell
model was applied as observed in the experimental study [51]. This experimental study
described that hERG mRNA expression was ~1.6 times more abundant in the EPI cells than in
the MIDDLE cells, consistent with the possible transmural heterogeneity of IKr density. Ten
Tusscher et al. [27] assumed a uniform IKr density in the ENDO, MIDDLE and EPI cell model.
However, when IKr density in the EPI cell was set to be 1.5–1.7 time greater than that in the
ENDO and MIDDLE cell, the 1D strand model was then able to generate a higher T-wave
Fig 5. Space-time plot of excitation prolongation across a 1D strand model, the computed pseudo-ECGs and QT intervals. (A) Excitation
prolongation across an ENDO-ENDO connection 1D strand model (i) and pseudo-ECGs (ii). Color mapping of membrane voltage along the 1D
strand from blue to red. Space runs from top (ENDO) to bottom (EPI). Time runs from left (0 ms) to right (800 ms). The corresponding pseudo-
ECGs derived from the propagating electrical excitation wave above. (B) Excitation prolongation across a 1D transmural ventricular strand model
(i) and pseudo-ECGs (ii). (C) Excitation prolongation across an EPI-EPI connection 1D strand model (i) and pseudo-ECGs (ii). (D) Superimposed
pseudo-ECGs (i) and corresponding QT interval (ii) in WT and drug-in-action conditions by using a 1D transmural ventricular strand model. (E)
Superimposed pseudo-ECGs (i) and corresponding QT interval (ii) in N588K and drug-in-action conditions by using a 1D transmural ventricular
strand model.
https://doi.org/10.1371/journal.pone.0179515.g005
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amplitude on the computed pseudo-ECG (S1 Fig in the Supporting Information). In Fig 5A(ii)
and 5C(ii), both ENDO-to-ENDO connection and EPI-to-EPI connection 1D models failed to
reproduce the major feature of SQTS ECG: a significant increase in the positive T wave ampli-
tude in the pseudo-ECG. In this study, we used the 1D transmural strand model (Fig 5B(ii))
with IKr ratio of 1.6:1:1 in the EPI, MIDDLE and ENDO cells to assess the drugs on SQT1.
Compared with the WT condition, the N588K mutation did not affect the depolarization
phase but accelerated the repolarization process of the ventricular tissue. Simulated E-4031,
disopyramide and quinidine delayed the repolarization phase in the both WT and N588K con-
ditions. The actions of the drugs caused QT prolongation and lower amplitude in the T-wave
morphology (Fig 5D(i) and 5E(i)). Then, we calculated QT intervals extracted from the simula-
tion data as showed in Fig 5D(ii) and 5E(ii) in WT and N588K conditions, respectively. The
pseudo-ECG traces show an increment in the QT interval in the presence of 3, 3.5 and 4 nM
E-4031, 9, 10 and 13 μM disopyramide, and 4, 7 and 10 μM quinidine, which changed from
394 (control) in the WT condition to 396, 398, 398, 404, 406, 408, 410, 424 and 458 ms, respec-
tively. For the same condition, the QT interval was prolonged from 286 in the N588K condi-
tion to 288, 288, 290, 330, 340, 350, 355, 382 and 405 ms, respectively. The N588K mutant QT
intervals in the presence of 7 and 10 μM quinidine are 382 and 405 ms, which are within the
physiological range of QT interval between 363 and 421 ms reported for 1 Hz stimulation fre-
quency, with a little difference of the stimulation frequency of 1.25 Hz in the present computer
simulations.
To examine the factors responsible for the significantly decreased T-wave amplitude, we
analyzed the effects of E-4031, disopyramide and quinidine on the AP heterogeneity (δV), as
well as the transmural dispersion of APD across the 1D strand tissue. The results are presented
in Fig 6. Differences of δV between EPI, MIDDLE and ENDO cells are shown in Fig 6A. Com-
pared with the WT condition, the N588K mutation increased the δV, which contributed to the
increased T-wave amplitude on the pseudo-ECG. With the presence of quinidine both in WT
and N588K conditions, the δVwas significantly decreased, which subsequently caused the
decreased T-wave amplitude. Spatial distribution of APD90 across the 1D transmural strand
model was shown in Fig 6B. With a ratio of 1.6:1:1 for the EPI IKr density to MIDDLE and
ENDO IKr density, the N588K mutation augmented dispersion of APD90 across the 1D strand
model. Quinidine decreased the dispersion (Fig 6C), which also subsequently caused the
decreased T-wave amplitude.
Simulation of the drug quinidine effects steepened the APD-R curve for the ventricular EPI
cell model and caused a rightward shift of the APD-R curve (see Fig 7A). The maximal slopes
of the APD-R were increased. These results suggested a regain of rate-adaptation of ventricular
APD, indicating anti-arrhythmic effects of quinidine on SQT1 M588K mutation. Simulation
of the drug quinidine effects also steepened the ERP-R curve for the ventricular EPI cell model
(Fig 7B) and caused a rightward shift of the ERP-R curve with increased maximal slopes.
These results also suggested a regain of rate-adaptation of ventricular ERP, also indicating
anti-arrhythmic effects of quinidine on SQT1 M588K mutation. The temporal vulnerability (vul-
nerable time window) of ventricular tissue to unidirectional conduction block was measured in
response to a test stimulus. Results are shown in Fig 7C. It was shown that the test stimulus was
applied sufficiently early, during and after the vulnerable time window that produced bidirec-
tional conduction block (Fig 7C(i)), unidirectional block (Fig 7C(ii)) and bidirectional conduc-
tion (Fig 7C(iii)), respectively. Fig 7C(iv and v) shows the width of the vulnerable time window,
during which a test stimulus led to unidirectional conduction block in the WT, N588K, drug-in-
action conditions. The measured vulnerable time window decreased from 1.5 ms in the WT
(control) condition to 1.43, 1.43, 1.42, 1.3, 1.27, 1.2, 1.1, 1.0 and 0.9 ms in the presence of 3 nM,
3.5 nM and 4 nME-4031, 9 μM, 10 μM and 13 μM disopyramide, and 4, 7 and 10 μM quinidine
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conditions, respectively, and it decreased from 3.1 ms in the N588K (control) condition to 3.0,
2.95, 2.9, 2.6, 2.5, 2.3, 2.1, 1.9 and 1.6 ms, respectively.
Effects of E-4031, disopyramide and quinidine on SQT1 in the 2D
regular and realistic tissue model
Fig 8 shows the re-entrant excitation waves via pseudo-color plots of cell APs. An S1 stimulus
was applied to the ENDO end to evoke an electrical excitation wave that propagated through
the MIDDLE and then towards the EPI in the WT (Fig 8A), N588K (Fig 8B) and quinidine-in-
action (Fig 8C) conditions. After a time delay (WT: 340 ms; N588K: 285 ms; N588K+ 10 μM
quinidine: 340 ms), an S2 was applied to the MIDDLE-EPI junction that produced a unidirec-
tional conduction, forming a re-entrant excitation wave. In the WT condition, the initiated re-
entry was unstable, which led to self-termination, as showed in Fig 8A(iv). Fig 8B(iv) shows
that the N588K mutation stabilized and sustained re-entry. Quinidine prevented re-entry as
shown in Fig 8C(iv). Fig 8A(v), 8B(v) and 8C(v) shows a recording of the evolution of the AP
of a cell in the tissue in the WT, N588K, quinidine-in-action conditions, respectively. Fig 8D
Fig 6. Action potential heterogeneity (δV) between single ENDO, MIDDLE and EPI cells, transmural APD90 distribution and its spatial gradient
along a 1D transmural strand model. (A) Plots of δV against time for WT (i), WT+10μM quinidine (ii), N588K (iii) and N588K+10μM quinidine (iv)
conditions, and maximal δV during repolarization process between ENDO-EPI cells in the WT (v) and N588K (vi) conditions. (B) Spatial distribution of APD90
across the 1D transmural strand in the WT, N588K and quinidine-in-action conditions. Dashed black lines for WT condition and solid black lines for N588K
condition, dashed gray lines for WT+10μM quinidine condition and solid gray lines for N588K+10μM quinidine condition. (C) The spatial gradient of APD90
across the 1D transmural strand in the WT (i), N588K (ii) and quinidine-in-action conditions, and maximal spatial gradient of APD90 in the WT (iii) and N588K
(iv) conditions.
https://doi.org/10.1371/journal.pone.0179515.g006
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shows the dominant frequency from 2.71 Hz for WT condition to 2.69, 2.68, 2.67, 2.51, 2.47,
2.43, 2.41, 2.38 and 2.30 Hz in the presence of 3 nM, 3.5 nM, 4 nM E-4031, 9 μM, 10 μM and
13 μM disopyramide, and 4, 7, and 10 μM quinidine conditions, and from 3.43 Hz for N588K
condition to 3.42, 3.41, 3.40, 3.25, 3.15, 3.05, 2.95, 2.78 and 2.68 Hz, respectively. We then pro-
ceeded to measure the minimum spatial size of the S2 during the vulnerable time window (Fig
8E). The estimated spatial length of the S2 increased from 71 mm in WT condition to 72, 73,
73, 76, 76, 77, 78, 80 and 82 mm in the presence of 3 nM, 3.5 nM, 4 nME-4031, 9 μM, 10 μM,
13 μM disopyramide, 4, 7 and 10 μM quinidine conditions, and increased from 41 mm in
N588K condition to 42, 43, 44, 50, 51, 54, 60, 65 and 70 mm, respectively. Prolongation of
APD due to the drug action increased the wavelength of the ventricular excitation wave and
increased the minimum length of S2 stimulus.
Results of 2D realistic human ventricular tissue are shown in Fig 9. In response to a test S2
stimulus applied in the ENDO region, within the vulnerable time window (WT: 340 ms;
Fig 7. APR-R and ERP-R curve of EPI cells and vulnerable time window along the 1D transmural strand. (A) APD-R curve (i) and maximal slope for
in the WT (ii) and N588K (iii) conditions. (B) ERP-R curve (i) and maximal slope for in the WT (ii) and N588K (iii) conditions. (C) Space-time plot of electrical
excitation propagation and response of the ventricular tissue to a test stimulus. APs are mapped into a color spectrum ranging from -85 mV to +45 mV.
Space runs from top (ENDO) to bottom (EPI). Time runs from left (0 ms) to right (400 ms). Bidirectional block (i). Unidirectional block (ii). Bidirectional
conduction (iii). Measured vulnerable time window width of the ventricular tissue in the WT (iv) and N588K (v) conditions.
https://doi.org/10.1371/journal.pone.0179515.g007
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N588K: 285 ms; N588K+10 μM quinidine: 340 ms), a re-entry was initiated in the left ventricu-
lar wall as shown in Fig 9A(ii) for the WT and Fig 9B(ii) for the N588K mutation and Fig 9C
(ii) for the N588K+10 μM quinidine conditions. Subsequent conduction of the induced wave
is shown by snapshots induced in Fig 9A(iii-v) for the WT and Fig 9B(iii-v) for the N588K and
Fig 9C(iii-v) for the N588K+10μM quinidine conditions. For the WT condition, the initiated
re-entrant excitation wave self-terminated (Fig 9A(v)). However, with the N588K mutation,
re-entrant excitation wave was sustained (Fig 9B(v)). With the application of 10 μM quinidine
in the N588K condition, wavelets were eliminated, and re-entrant excitation wave was termi-
nated by meandering out of tissue border (Fig 9C(v)). Similar results were observed from 2D
idealized, regular models. Though the termination was due to re-entry meandering, this is also
considered to be antiarrhythmic as there are many non-excitation regions (i. e., connective tis-
sues, opening valves) in the ventricles which can be taken as tissue borders.
Discussion
Summary of the major findings
The proband in whom the KCNH2 N588K mutation was identified had a QTc interval of 288
ms, whereas his son had a QTc of 293 ms. It is of particular note that with the use of quinidine,
mimicking the effects on the proband, we found that the simulated QT interval extended from
286 ms in the N588K condition to 382 and 405 ms in the presence of 7 and 10 μM quinidine,
Fig 8. Snapshots of initiation and propagation of re-entry in 2D regular ventricular models. (A) A planar wave generated by S1 at the ENDO end,
which propagates through the MIDDLE and then towards the EPI in the WT condition. Snapshots at time = 10 ms (i). The S2 applied to the MIDDLE-EPI
junction during the vulnerable time window of the ventricular tissue. Snapshots at time = 340 ms (ii), 650 ms (iii), 2000 (iv) and evolution of the AP of an EPI
cell (v). (B) Snapshots of re-entry in the N588K condition at 10 ms (i), 285 ms (ii), 650 ms (iii), 2000 ms (iv) and evolution of the AP of an EPI cell. (C)
Snapshots of re-entry in the N588K+10μM quinidine condition at 10 ms (i), 340 ms (ii), 650 ms (iii), 2000 ms (iv) and evolution of the AP of an EPI cell.
Quinidine at a dose of 10 μM prevented re-entrant wave in the N588K condition. (D) Computed dominant frequency of electrical activity recorded from the
ventricle in WT (i) and N588K (ii) conditions. (E) Measured minimal spatial length of a test stimulus that provides a sufficient substrate for the formulation of a
re-entrant circuit in WT (i) and N588K (ii) conditions.
https://doi.org/10.1371/journal.pone.0179515.g008
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which is within the normal range of QT interval between 363 and 421 ms. The findings are
summarized as follows: (i) the simulated drugs E-4031 and disopyramide had hardly notice-
able effects on APD, whereas quinidine caused a significant prolongation of APD; (ii) quini-
dine extended the QT interval on the computed pseudo-ECG, and decreased the T-wave
amplitude, close to that in the WT condition; (iii) quinidine prolonged ventricular cell APD90
across the ventricle wall, and decreased transmural dispersion of APD; (iv) quinidine
decreased the maximal transmural AP heterogeneity (δV), which contributed to the decreased
T-wave amplitude; (v) quinidine decreased the tissue temporal vulnerability to the genesis of
uni-directional conduction by a test stimulus; (vi) quinidine increased the minimal substrate
size of tissue that required to initiate and maintain re-entrant waves, and prevented and termi-
nated re-entrant waves as shown in both regular and realistic tissue models of the human ven-
tricle; (vii) quinidine exhibited significantly better therapeutic efficacy than E-4031 and
disopyramide. These major findings substantiate the causal link between the antiarrhythmic
drug quinidine and QT interval prolongation and the decreased T-wave amplitude and, more-
over, provide an explanation for decreased susceptibility to re-entry and prevention and termi-
nation of re-entrant arrhythmia in SQT1 patients.
Significance of the Study
Previous studies [12,13] have used a mathematical model of the heart to investigate the pro-
arrhythmic effects of hERG N588K mutation on ventricular cell APD shortening and
Fig 9. Snapshots of initiation and propagation of re-entry in 2D realistic ventricular models. (A) An excitation wave generated by S1 at
the ENDO end in the realistic 2D model cross-section of ventricles in the WT condition. Snapshots at time = 2 ms (i). Application of a test S2
stimulus into the refractory. Snapshots at time = 340 ms (ii). Snapshots of the spiral wave at time = 500 ms (iii), 800 ms (iv) and 2000 ms (v). (B)
Snapshots of re-entry in the N588K condition at 2 ms (i), 285 ms (ii), 500 ms (iii), 800 ms (iv) and 2000 ms (v). The induced spiral wave persisted
in N588K condition and broke-up forming regenerative multiple re-entrant wavelets. (C) Snapshots of re-entry in the N588K+10μM quinidine
condition at 2 ms (i), 340 ms (ii), 500 ms (iii), 800 ms (iv) and 2000 (v). 10μM quinidine terminated the multiple wavelets.
https://doi.org/10.1371/journal.pone.0179515.g009
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characteristics of computed pseudo-ECGs. However, simulations addressing the effects of
antiarrhythmic drugs on ventricular cell AP and tissue have not been performed until now.
Furthermore, our simulations were able to reproduce the known effects of hERG N588K muta-
tion on the electrophysiological activity of the ventricles, which provided the first step towards
the validation of the use of the cardiac model in assessing the effects of drugs on SQT1.
Data regarding pharmacological therapy for SQT1 are very limited [52]. An only prior
experimental study [17] employing the whole-cell patch clamp, has used five canonical inhibi-
tors including E-4031, amiodarone, quinidine, propafenone and disopyramide, to investigate
the link between impaired inactivation and altered drug potency. Nevertheless, it did not
examine whether or not these drugs would prolong the QT interval in SQT1 conditions. The
present study extends our previous work [13] demonstrating the mechanisms by which the
hERG N588K mutation facilitates and perpetuates ventricular arrhythmias. Here, we focus on
investigating the pharmacology for SQT1 related N588K mutation in KCNH2. The different
drugs including E-4031, disopyramide and quinidine have been studied. Our results showed
that once the drugs were applied, the APD90 of each cell was lengthened, QT interval was pro-
longed and T-wave amplitude was decreased. As expected, the QT interval prolongation is
explained by an APD prolongation caused by drugs, whereas the decrease in the T-wave ampli-
tude correlates with a reduced dispersion of repolarization. Previous studies [53–55] have
linked changes in T-wave amplitude, which is the gradient of the transmembrane potential in
the ventricles. Moreover, the fundamental importance of the maximal transmural AP hetero-
geneity and APD90 dispersion in SQTS has been demonstrated in our previous studies
[13,37,46]. To elucidate the effects of E-4031, disopyramide and quinidine on the maximal
transmural AP heterogeneity and APD90 dispersion, the action of drugs on a ventricular strand
model has been studied. In this study, we quantified the ventricular gradient by computing the
dispersion of the ventricular APD90 across the ventricular wall; we found that drugs caused
decreased APD dispersion and the maximal transmural AP heterogeneity. A direct correlation
was observed between the changes in APD and the QT interval caused by drugs. These changes
can account not only for a prolonged QT interval but can also account for a decreased T-wave
amplitude.
Quinidine decreased tissue’s temporal vulnerability for unidirectional conduction block
and increased the critical size of the tissue necessary to accommodate re-entrant waves, thus
suppressing the initiation and maintenance of re-entrant excitation waves. This result was due
to the prolonged APD and ERP and wavelength of excitation waves. Therefore, the re-entrant
wave was initiated with greater difficulty, owing to the longer APD and ERP and larger wave-
length of the re-entrant excitation wave. In the 2D realistic tissue model, the multiple re-
entrant wavelets were terminated in the presence of quinidine, indicating that a transition
from fibrillation-like to control (WT) electrical excitation waves.
Limitations of the study
Limitations of the ten Tusscher et al. [27] model for human ventricular myocytes have been
discussed in detail elsewhere [13,27,37,46], so that will not be covered again here. Although
such a model is not as complete as the newest model [36], it is sufficient for the purpose of this
study as the simulated effects of quinidine on SQT1 are in accordance with the clinical phe-
nomenon. In this study, we did not consider the effect of the atria, mechano-electric coupling
and feedback, and coronary flow, which might influence the effects of drugs on SQTS.
In this study, the SQT1 data extracted from literature [17] are on homozygous mutant
channels (N588K/N588K) versus wild-type channels (WT/WT). Accordingly, simulations
were performed on carriers of the homozygous N588K rather than SQT1 patients, who are
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heterozygous (WT/N588K). Therefore, for future work, integration of heterozygous (WT/
N588K) data could provide better insight into the effects of quinidine on SQT1 patients.
Another shortcoming is the absence of beta subunits that may interfere with the IKr kinetics,
e.g., Mink-related peptide 1 (MiRP1, encoded by the gene KCNE2), as demonstrated by
McPate et al. [28]. Furthermore, there are more experimental data on the N588K mutation
than those reported by McPate et al. [17], i. e., studies by Brugada et al. [5] and Grunnet et al.
[56]. Consideration of a combination of those N588K mutation data could facilitate more thor-
ough investigations of SQT1.
The action of drugs at the ion channel level was simulated using a simple pore block theory
[29]. This method did not incorporate voltage-, state-, frequency-dependent block effects, but
it successfully reproduced the required drug-induced decrease in conductance. The use of the
simple pore block theory is justified by the match between simulation data and clinical data. In
our simulations, the results of quinidine on SQT1 are consistent with the clinical studies (see
Discussion section). Regarding the experimental conditions, many factors that can influence
the binding of a drug to ion channels are increasingly being modeled, including oxygen, the
concentration of ions, temperature and pH [57,58]. However, pharmacological screening does
not usually record sufficient data [58]. For conditions with variable pacing rates, conductance
block approximation may be insufficient for the simulation of drug actions.
Nevertheless, whilst it is important that potential limitations are made explicit, these limita-
tions do not influence fundamentally the conclusions that can be drawn on likely mechanisms
by which quinidine prevents and terminates arrhythmias in SQT1.
Conclusions
As the SQTS patient is very rare, extensive clinical trials are currently not feasible. However, in
silico approach can be a powerful tool for assessing drug-induced APD/QT interval prolonga-
tion, as well as helping to dissect underlying mechanisms. In this study, we presented a simula-
tion study showing the antiarrhythmic effects of quinidine, disopyramide and E-4031 on
SQT1. On the basis of the simulations, it can be concluded that antiarrhythmic drug quinidine
causally not only linked to QT interval prolongation but also caused to decreased APD disper-
sion and maximal transmural AP heterogeneity (δV), which contributed to the decreased T-
wave amplitude. Additionally, quinidine reduced tissue’s temporal vulnerability to the genesis
of re-entry by a test stimulus and increased tissue ERP that prevented and terminated re-
entrant excitation waves in the 2D regular and realistic tissues. In conclusion, on one hand, the
findings of this study provide an explanation for clinical phenomenon of treating SQT1 patient
by quinidine, and demonstrate antiarrhythmic effects of quinidine on SQT1 and suggest quini-
dine is a potential pharmacological agent for treating SQT1 patients; on the other hand, the
ventricular models used in this study may have further utility for probing the pharmacological
effects of other antiarrhythmic agents on SQTS.
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S1 Text. An appendix showing the IKr Markov chain model equation parameters for WT
and N588K conditions.
(DOCX)
S1 Fig. Pseud-ECGs for the different EPI: MIDDLE: ENDO IKr density ratios of 1.0:1:1,
1.5:1:1, 1.6:1:1 and 1.7:1:1. (A) In WT condition. (B) In N588K condition.
(TIF)
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S1 Video. WT re-entry in a 2D regular tissue. Initiation and conduction of re-entrant excita-
tion waves in a 2D regular model of the transmural ventricle under the WT condition. A pla-
nar wave generated by an S1 stimulus at the ENDO end propagates through MIDDLE and
then towards the EPI end. An S2 stimulus is applied to the EPI-MIDDLE junction during the
vulnerable time window at 340 ms, which develops into a re-entrant excitation wave. The re-
entrant excitation wave self-terminates within 2000 ms.
(MP4)
S2 Video. N588K re-entry in a 2D regular tissue. Initiation and conduction of re-entrant
excitation waves in a 2D regular model of the transmural ventricle under the N588K condition.
A planar wave generated by an S1 stimulus at the ENDO end propagates through MIDDLE
and then towards the EPI end. An S2 stimulus is applied to the EPI-MIDDLE junction during
the vulnerable time window at 285 ms, which develops into a re-entrant excitation wave. The
re-entrant excitation wave persists under the N588K mutant condition.
(MP4)
S3 Video. N588K+quinidine re-entry in a 2D regular tissue. Initiation and conduction of re-
entrant excitation waves in a 2D regular model of the transmural ventricle under the WT con-
dition. A planar wave generated by an S1 stimulus at the ENDO end propagates through MID-
DLE and then towards the EPI end. An S2 stimulus is applied to the EPI-MIDDLE junction
during the vulnerable time window at 340 ms, which develops into a re-entrant excitation
wave. The re-entrant excitation wave self-terminates within 2000 ms.
(MP4)
S4 Video. WT re-entry in a 2D realistic tissue. Re-entrant excitation wave generated by a test
S2 stimulus during the vulnerable time window at 340 ms. The initiated re-entrant excitation
wave self-terminates within 2000 ms.
(MP4)
S5 Video. N588K re-entry in a 2D realistic tissue. Re-entrant excitation wave generated by a
test S2 stimulus during the vulnerable time window at 285 ms. The initiated re-entrant excita-
tion wave transition from transmural re-entrant wave with tip rotating within the ventricle
wall to anatomical re-entrant wave with tip rotating around the ventricle boundary. The re-
entrant excitation wave persists under the N588K condition and breaks up forming multiple
re-entrant wavelets.
(MP4)
S6 Video. N588K+quinidine re-entry in a 2D realistic tissue. Re-entrant excitation wave
generated by a test S2 stimulus during the vulnerable time window at 340 ms. With the appli-
cation of quinidine in the N588K condition, the initiated re-entrant excitation wave was termi-
nated within 2000 ms.
(MP4)
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